Quick answer
What is Larazotide?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Larazotide is a peptide, grouped on this site under Tissue repair peptides, and the 12 research records kept here are 4 from studies in rats or mice, 1 from a trial in people and 7 that do not state what kind of study it is.
The literature search returned 45 records. This site keeps 12 of them, which is 27 per cent of what came back.
What it is
This site puts it in the Tissue repair peptides group.
A zonulin inhibitor reported in the retrieved records to regulate epithelial tight junctions and promote their assembly.[1, 2, 3]
Stated in the titles of the cited 2012 Peptides papers and the 2021 Current Medicinal Chemistry review.
What kind of records
A small number of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 1 interventional human trial record among 12 indexed records.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 33 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides (2012). pmid:22401908
- Larazotide acetate promotes tight junction assembly in epithelial cells. Peptides (2012). pmid:22401910
- The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases. Current medicinal chemistry (2021). pmid:33397225